T Central Memory Cells in Early Localized Non-Segmental Vitiligo

Cairo University22 enrolled

Overview

Assessing the level of circulating TCMs (cluster of differentiation (CD) 8+, CD3+,C- chemokine receptor (CCR)7, cluster of differentiation 45 receptor (CD45R) cells) in early localized vitiligo cases prior to treatment and after treatment in comparison to healthy controls. This, in turn, would provide insights regarding the role of TCMs in vitiligo and the role of early treatment in halting disease progression and autoimmune memory formation that accounts for high recurrence rate of vitiligo

Assessing the level of circulating TCMs (CD8+ CD3+ CCR7+ CD45RO+ cells) in early localized vitiligo cases where samples will be processed and stained for CD8, CD3, CCR7, . CCR7, CD45R. Multi-parametric flow cytometry will be used to quantify CD3+ve, CD8+ve, CCR7+ve, CD45RO+ve TCM cells percentage, which will be expressed as a percentage from the total lymphocyte gate. This will be done prior to treatment and after treatment and will be compared to healthy controls.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Vitiligo

Interventions

oral mini pulseDRUG

5mg / week oral dexamethasone

Topical creamDRUG

topical fluticasone cream for body lesions and topical tacrolimus for face lesions

targeted phototherapyDEVICE

twice weekly targeted excimer light sessions

Eligibility

Sex: ALLMin age: 12 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: \- Subjects with vitiligo localized to one anatomical area, of ≤ 6 months' duration Exclusion Criteria: * Patients who received treatment of any type (topical or systemic) within the last 3 months

Locations (1)

Cairo university hospitals, dermatology outpatient clinic

Cairo, Egypt

Outcomes

Primary Outcomes

comparing level of circulating central memory T cells (TCM) in early localized vitiligo cases to healthy controls

comparing TCM levels in early localized vitiligo cases prior to and after treatment to healthy controls

Time frame: 6 months

percent change in the level of circulating central memory T cells (TCM) in early localized vitiligo cases after treatment

assessing the level of circulating central memory T cells (TCM) in early localized vitiligo cases after treatment and calculating percent change in their levels

Time frame: 6 months

comparing percent change in the level of circulating central memory T cells (TCM) in early localized vitiligo cases after treatment in those receiving systemic treatment to those receiving only topical treatment

assessing the level of circulating central memory T cells (TCM) in early localized vitiligo cases after treatment and calculating percent change in their levels in those receiving systemic treatment to those receiving only topical treatment

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.